Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™
News provided by
Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™.
Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases. The designation expedites the traditional development, assessment and review process, and enables medical professionals to get access to new developments quickly.
Cerus Endovascular Announces the First Ever Robotic Assist Intracranial Implant of its Contour Intrasaccular Device
Groundbreaking Aneurysm Procedure Completed in 28 Minutes
News provided by
Share this article
Share this article
FREMONT, Calif. and OXFORD, United Kingdom, Dec. 17, 2020 /PRNewswire/ Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced the first ever robotically assisted intracranial implant of its Contour intrasaccular device. The groundbreaking procedure was completed at the King Edward Memorial Hospital, Mumbai, by renowned neurosurgeon, Dr. Nitin Dange and was performed on a Middle Cerebral Aneurysm with a 7mm Contour device. Procedural time, including access and placement of the Contour, took a total of 28 minutes.